DEPARTMENT OF
BUDGET & MANAGEMENT

LARRY HOGAN
Governor

BOYD K. RUTHERFORD
Lieutenant Governor

DAVID R. BRINKLEY
Secretary

MARC L. NICOLE
Deputy Secretary

Amendment #13 to Request for Proposals (RFP)
NO. F10B6400005R
Department of Budget & Management
Pharmacy Benefit Management Services and Pharmacy Benefits
Purchasing Pool Management
December 1, 2016

This Amendment is being issued to amend and clarify certain information contained in the above named RFP. All information contained herein is binding on all Offerors who respond to this RFP. Specific parts of the RFP have been amended. The following changes/additions are listed below. New language has been double underlined and marked in bold (ex. **new language**), and language deleted has been marked with a strikeout (ex. ~~language deleted~~).

The Department is issuing the below extension to allow for its consideration of and response to additional vendor questions related to the RFP specifications.

1. AMEND RFP Section 1.2.5 "Brand Drug" definition as follows:

A drug that is approved by the U.S. Food and Drug Administration (FDA) and is distributed under an FDA Application Type of new drug application (NDA) or biologic license application (BLA), and which is not an authorized generic (marketed as a generic under private label) and which is not processed with DAW code 5. All financial guarantees will be reconciled based on the above definition. In instances where the brand or generic status of a drug, as determined by the Contractor relying on an independent published source, differs from this definition, the Contractor may rely on its standard drug classification system for operational purposes such as claim adjudication. **Any drug that does not meet the definition of either Brand Drug, per this definition, or Generic Drug, per the definition in Section 1.2.39, shall be excluded from Financial Proposal Form (Attachment F) pricing guarantees and reconciliation of those guarantees for FA 1 and FA 2, but will be subject to the Transparent and Pass Through Pricing requirements of RFP Section 3.2.2.**

2. AMEND RFP Section 1.2.24 "DESI" definition as follows:

Drug Efficacy Study Implementation. DESI refers to drugs identified by the Food and Drug Administration as lacking substantial evidence of effectiveness. ~~For the purpose of this RFP, DESI includes any drugs distributed under an FDA Application Type other than abbreviated new drug application (ANDA), new drug application (NDA), or biologic license application (BLA).~~ DESI drugs**, as with all other drugs that do not meet the definition of either Brand Drug, per RFP Section 1.2.5, or Generic Drug, per RFP Section 1.2.39,** ~~with a DESI indicator of 5 or 6will~~ **shall** be excluded from **Financial Proposal Form (Attachment F) pricing guarantees and** reconciliation of **those** guarantees

for ~~RFP~~ FA 1 and FA 2**, but will be subject to the Transparent and Pass Through Pricing requirements of RFP Section 3.2.2.**

3. AMEND RFP Section 1.2.39 "Generic Drug" definition as follows:

A drug that is approved by the U.S. Food and Drug Administration (FDA) and is distributed under an FDA Application Type of abbreviated new drug application (ANDA), or which is an authorized generic (marketed as a generic under private label) or which is processed with DAW code 5. All financial guarantees will be reconciled based on the above definition. In instances where the brand or generic status of a drug, as determined by the Contractor relying on an independent published source, differs from this definition, the Contractor may rely on its standard drug classification system for operational purposes such as claim adjudication. **Any drug that does not meet the definition of either Generic Drug, per this definition, or Brand Drug, per the definition in RFP Section 1.2.5, shall be excluded from Financial Proposal Form (Attachment F) pricing guarantees and reconciliation of those guarantees for FA 1 and FA 2, but will be subject to the Transparent and Pass Through Pricing requirements of RFP Section 3.2.2.**

Issued and authorized by

<signed>
Rachel Hershey
Procurement Officer